Abstract:
This article reflects some aspects of the complex process of medicines price reglementation. The system of regulation of medicines prices which exists in the republic has serious shortcomings, and it is very useful to study the experience of other countries in this domain in order to improve. One way to reduce spendings on medicines is to stimulate the use of so-called generics - medicines that have proven therapeutic bioequivalence with an original preparation of a similar composition for which has expired the protection of the patent. The prices of medicines which costs are entirely or partially reimbursed from the State budget or mandatory health insurance, as well as the medicines sold to the general public only on prescription, are regulated by the State in all European countries. Insurance companies and State monitors and controls the mode of pricing by producers of medicines. The prices of medicines, as a rule, is calculated by the method of cost, including the cost of ingredients, production costs, marketing and innovation expenditures, loans and profits at a later date which will ensure further development of the enterprise. For the responsible authorities in the country would be beneficial to consider both the positive aspects and possible risks arising from the use of regulatory measures from European countries with rich experience in the pharmaceutical industry.
